Previous 10 | Next 10 |
Companies focused on a class of drugs known as T-cell engagers are trading higher Tuesday after AstraZeneca ( NASDAQ: AZN ) announced an agreement to acquire the U.S.-based TeneoTwo for a total consideration of up to $1.3B. The acquisition will further diversify its hema...
CytomX Therapeutics (NASDAQ:CTMX) stock rose ~4% on June 24 after BMO Capital began coverage of the stock with an Outperform rating and a $9 target price. The SA Quant Rating on the stock is Hold, which factors in measures such as Profitability and Growth. The rating is in contrast to the ave...
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at ...
CytomX Therapeutics (NASDAQ:CTMX) said the first patient was dosed in a phase 1 dose-escalation study of CX-904 in patients with advanced solid tumors. "The successful initiation of this first-in-human study represents another major milestone for CytomX, as it marks the third therapeutic...
SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 ( NCT05387265 ...
CytomX Therapeutics, Inc. (CTMX) Q1 2022 Earnings Conference Call May 5, 2022, 5:00 pm ET Company Participants Chau Cheng - VP, IR & Corporate Communications Sean McCarthy - CEO & Chairman Amy Peterson - President & COO Carlos Campoy - CFO Conference Call Participants Kaveri Pohlm...
Image source: The Motley Fool. CytomX Therapeutics (NASDAQ: CTMX) Q1 2022 Earnings Call May 05, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: CytomX Therapeutics (CTMX) Q1 2022 Earnings Call Transcript
CytomX press release (NASDAQ:CTMX): Q1 GAAP EPS of -$0.37 misses by $0.01. Revenue of $17.13M (+7.3% Y/Y) misses by $4.12M. For further details see: CytomX GAAP EPS of -$0.37 misses by $0.01, revenue of $17.13M misses by $4.12M
- Patient enrollment completed in Arm A in the Phase 2 study of praluzatamab ravtansine in breast cancer, initial data for both Arms A and B on track for second half of 2022 - - Phase 2 expansion study of CX-2029 ongoing, patient enrollment completed for squamous non-small cell ...
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...